In the Core Curriculum in Nephrology installment entitled “Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022” that appeared in the September 2022 issue of AJKD,1 there was a typographical error in Figure 1, in which “obinutuzumab” was incorrectly rendered as “obintuzumab”. A corrected version of the figure is provided here.